MAR 1 6 2007

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on the date shown below:

INFORMATION DISCLOSURE STATEMENT
Patent Application
Docket No. GJE-1080

Serial No. 10/580,769

March 14, 2007

David R. Saliwanchik, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit

1751

Applicant(s)

Christopher Iain Grainger

Serial No.

10/580,769

Filed

May 26, 2006

For

Stabilisation of Viral Microparticles

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

The above-identified patent application was filed in the U.S. Patent Office as a national application under 35 USC §371. A copy of the International Search Report and copies of the references cited therein have been made available in the national stage file.

However, for the examiner's convenience, the applicant is attaching a copy of the International Search Report as well as copies of the documents cited therein. Also attached is Form PTO/SB/08 listing the references.

In accordance with 37 CFR §1.56, the applicant hereby requests that the references cited in the International Search Report and listed on the attached form PTO/SB/08 be made of record and considered in the examination of the subject application. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

The applicant respectfully asserts that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

David R. Saliwanchik

Patent Attorney

Registration No. 31,794 Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

DRS/wrc

Attachments: Form PTO/SB/08 (3 pages)

International Search Report Copies of references cited (17)



Sheet

PTO/SB/08A (07-05) Approved for use through 07/31/2006.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known			
Application Number	10/580,769		
Filing Date	May 26, 2006		
First Named Inventor	Christopher lain Grainger		
Art Unit	1751		
Examiner Name	Not yet assigned		
Attorney Docket Number	G.IF-1080		

	U.S. PATENT DOCUMENTS					
Examiner	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines, Where	
Initials*	No. 1	Number - Kind Code ^{2 (if known)}		of Cited Document	Relevant Passages or Relevant Figures Appear	
	U1	US-				
	U2	US-				
	U3	US-		•		
	U4	US-			-	
	U5	US-				
	U6	US-				
	U7	US-				
	U8	US-				
·	U9	US-				
	U10	US-				
	U11	US-				
	U12	US-				
	U13	US-				

3

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Τ¢
	F1	GB 2 395 900 A	06-09-2004	Elan Drug Delivery Limited	All	
	F2	WO 96/03978 A1	02-15-1996	Quadrant Holdings Cambridge Limited	All	
	F3	WO 99/55362 A1	11-04-1999	Genentech, Inc.	All	
	F4	WO 00/00215 A1	01-06-2000	Alliance Pharmaceutical Corp.	All	
	F5	WO 02/32398 A2	04-25-2002	Massachusetts Institute of Technology	All	
	F6	WO 02/066005 A1	08-29-2002	Cambridge Biostability Ltd.	All	
	F7					
	F8					
	F9					

<u></u>		
Examiner	Date	
	Date	
Signature	Considered	
o.g.la.a.o	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. Complete if Known

10/580,769

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

Filing Date May 26, 2006 **First Named Inventor** Christopher lain Grainger Art Unit 1751 (use as many sheets as necessary) **Examiner Name** Not yet assigned GJE-1080 of Attorney Docket Number 3

Application Number

	 	NON PATENT LITERATURE DOCUMENTS	1
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	AGUADO, M.T. et al., "Injectable solid vaccines: a role in future immunization?", WHO Drug Information, 1998, pages 68-69, Vol. 12, No. 2.	
	R2	BOEHM, G. et al., "On Technological and Immnunological Benefits of Multivalent Single-Injection Microsphere Vaccines," Pharmaceutical Research, September 2002, pages 1330-1336, Vol. 19, No. 9.	
	R3	CAMBRIDGE BIOSTABILITY LTD, "Technology Overview: Single Shot Stable Liquid Vaccines and Snapjet Delivery Technology," October 2003, pages 1-30, Retrieved from the Internet: http://holdsworth.3ev.com/fileadmin/downloads/overview.doc	j. c
	R4	GRIBBON, E.M. et al., "Stabilisation of Vaccines Using Trehalose (Q-T4) Technology," Developments in Biological Standardization, 1996, pages 193-199, Vol. 87.	
	R5	LICALSI, C. et al., "Dry powder inhalation as a potential delivery method for vaccines," Vaccine, January 1999, pages 1796-1803, Vol. 17, Nos. 13-14.	
	R6	THE NEW TECHNOLOGIES WORKING GROUP OF THE GAVI RESEARCH AND DEVELOPMENT TASK FORCE, "Report Prepared for the Board of the Global Alliance for Vaccines and Immunization (GAVI)," May 30, 2003, pages 1-124, Retrieved from the Internet: http://www.vaccinealliance.org/resources/NTWG global.pdf>	
	R7	ROSER, B., "Trehalose Drying: A Novel Replacement for Freeze-Drying," <i>Biopharm.</i> , September 1991, pages 47-53, Vol. 4, No. 8.	
	R8	SMITH, D. et al., "Evaluation of Novel Aerosol Formulations Designed for Mucosal Vaccination Against Influenza Virus," Vaccine, June 2003, pages 2805-2812, Vol. 21, Nos. 21-22.	
	R9	TAMEZ-GUERRA, P. et al., "Storage stability of Anagrapha falcifera nucleopolyhedrovirus in spray-dried formulations," Journal of Invertebrate Pathology, January 2002, pages 7-16, Vol. 79, No. 1.	
	R10	WANG, L. et al., "Basic immunological properties of spray-dried lipid microparticles developed for nasal and systemic administration of vaccines," S.T.P. Pharma Sciences, January 2002, pages 53-61, Vol. 12, No. 1.	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. Complete if Known Substitute for form 1449/PTO **Application Number** 10/580,769 INFORMATION DISCLOSURE **Filing Date** May 26, 2006 STATEMENT BY APPLICANT **First Named Inventor** Christopher lain Grainger Art Unit 1751 (use as many sheets as necessary) **Examiner Name** Not yet assigned

Attorney Docket Number

GJE-1080

	Ι	NON PATENT LITERATURE DOCUMENTS	1
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	R11	WORRALL, E.E. et al., "Xerovac: an ultra rapid method for the dehydration and preservation of live attenuated Rinderpest and Peste des Petits ruminants vaccines," Vaccine, 2001, pages 834-839, Vol. 19, Nos. 7-8.	
	R12		
	R13		
	R14		
	R15		
	R16		
	R17		
	R18		
-	R19		
	R20		

Examiner	Date
Signature	Considered

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Sheet

of

3

3

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.